The response rate of PD-1/PD-L1 inhibitors predicted according to CMTM6 expression in CD163+ M2 macrophages was 66.7% (2/3) in dMMR CRC patients and 75% (3/4) in pMMR CRC patients. The gene discussed is CD163; the disease is colorectal carcinoma.